Featured Entrepreneurs

Since 2010, MassChallenge has accelerated 2,344 startups that have raised more than $5 billion in funding, generated more than $2.7 billion in revenue, and created more than 126,000 total jobs. 

Our startups

Be inspired. Search our startups.


Combioxin develops disruptive life-saving solutions that revolutionize the treatment severe infections such as pneumonia, the most frequent and deadliest infectious disease. CAL02 has been ranked a “milestone” and “medical breakthrough”. CAL02 provides a totally new and eagerly awaited solution. This non-antibiotic drug is a universal toxin trap used on top of any antibiotic and regardless of resistance. CAL02 will transform standard of care and reduce cost of care for millions of patients.
Combioxin develops innovative life-saving solutions that revolutionize standard of care for patients with severe infections

Connect with Combioxin


2019 Finalist Switzerland

Sub industry

Therapeutics (Pharma / Biotech)


MassChallenge strengthens the global innovation ecosystem by accelerating high-potential startups across all industries, from anywhere in the world.